Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

hts to its TRAIL receptor antibodies, HGS has agreed to a reduction in the royalties to which it is entitled from GSK if Syncria is commercialized. The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million and remain unchanged in the amended agreement. Syncria, a novel long-acting form of GLP-1 (glucagon-like peptide-1), was created by HGS using its proprietary albumin-fusion technology. GSK has exclusive rights to develop and commercialize Syncria, and is developing it for use in the treatment of type 2 diabetes. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance Syncria to Phase 3 development.

"We view our oncology portfolio as the cornerstone of our mid-stage pipeline, and as a key driver of future growth beyond the launch of our late- stage products," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "Reacquiring the rights to our TRAIL antibodies gives us the opportunity to drive and advance this growing program. We will continue to explore the possibility of bringing in additional new products, as well as forming new partnerships to add expertise and near-term financial resources in support of our pipeline."

HGS reported that a 2002 agreement with the Pharmaceutical Division of Kirin Brewery Company, Ltd. for joint development of antibodies to TRAIL receptor 2 has also been terminated.

About the HGS-ETR1 Proof-of-Concept Program

HGS-ETR1 is the most advanced of any product in development that targets the TRAIL apoptosis pathway. HGS has advanced HGS-ETR1 to a proof-of-concept phase consisting of three randomized Phase 2 chemotherapy combination trials to evaluate its potential in the treatment of specific cancers:

-- HGS has completed the enrollment and initial dosing of 105 patients in

a randomized Phase 2 trial of HGS-ETR1 in c
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... A major challenge before new biotechnology ... realm of Boston-Cambridge, is gaining visibility that can lead ... the Director of Boston’s Adult Stem Cell Technology Center, ... visibility of his company an important priority since he ... to a social media marketing campaign launched ...
(Date:8/28/2014)... SAN DIEGO, California, USA (PRWEB) August 28, 2014 ... at the Department of Physics and Optical Science and ... at the University of North Carolina at Charlotte, and ... has been elected to serve as the 2015 Vice ... photonics. , SPIE 2014 President Philip Stahl announced recent ...
(Date:8/28/2014)... Nevada City, Ca. (PRWEB) August 28, 2014 ... an E3 rating for an alcohol-based hand sanitizer, asks ... fall harvest by comparing the hand sanitizer they’re currently ... Sanitizer Spray . Hand hygiene is critical to fighting ... processing environment. Best Sanitizers believes there are key ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... Lentigen Corporation, a biotechnology company specializing in the ... and Expression Therapeutics, a biotechnology company specializing in ... to co-develop novel cell and protein therapies for ... disorder caused by a mutation in the factor ...
... Kendle (Nasdaq: KNDL ) announced today that ... the market closes on Tuesday, Feb. 24, 2009. The Company ... Wednesday, Feb. 25 at 8:30 a.m. Eastern Time. A question ... , To participate in the telephone conference call, interested parties ...
... Feb. 4 On the heels of a strong start ... executives will explain to investors this month where the company ... this year and how it plans to achieve its goal ... by fiscal 2012. Terry Crews, chief financial officer, and Carl ...
Cached Biology Technology:Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 2Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Monsanto Executives to Discuss Company's Growth Drivers, Profit Goals at Investor Conferences in February 2
(Date:9/1/2014)... how the alteration of a single nucleotidethe basic building block of ... intellectual disability. The study appears in The Journal of ... caused by a defect in a gene on the X chromosome ... in 230 women and 1 in 360 men carry a so-called ... of the FMR1 gene is slightly longer than normal. ...
(Date:8/31/2014)... University of Warwick have discovered that ,good, cholesterol is ... substance, methylglyoxal - MG, was found to damage ,good, ... from the body. , Low levels of HDL, ... with increased levels of MG being common in the ... , Supported by funding from the British Heart Foundation ...
(Date:8/31/2014)... busy attacking us, germs go after each other. But ... for the infected microbes: Sometimes viruses actually carry helpful ... its diet or better attack its own hosts. , ... system would robotically destroy anything it recognized as invading ... now revealed that one variety of the bacterial immune ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... & EMS Management Software Provider to Offer Biometrics, ... award-winning,fingerprint biometrics research and development firm, announced today ... Data Systems(R), an,industry leader in the development of ... software and hardware to ZOLL Data,Systems, customers., ...
... 10, 2008 -- The National Institutes of Health (NIH) ... College Assistant Professor of Biology Lara D. Hutson, in ... CMT is the most common inherited neuromuscular disease, ... CMT usually shows dominant inheritance and symptoms generally appear ...
... Human cancer cells divide and conquer. Unless physicians can ... wildly dividing cells will eventually destroy a person,s life. ... an enzyme called telomerase is crucial to cancer,s progress. ... of Georgia,s Franklin College of Arts and Sciences have ...
Cached Biology News:M2SYS Technology Selected by ZOLL Data Systems to Integrate Fingerprint Software 2UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: